» Articles » PMID: 30195892

Longitudinal Relationship Between Retinal Diabetic Neurodegeneration and Progression of Diabetic Retinopathy in Patients With Type 2 Diabetes

Overview
Journal Am J Ophthalmol
Specialty Ophthalmology
Date 2018 Sep 10
PMID 30195892
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate the longitudinal relationship between diabetic retinal neurodegeneration and the progression of diabetic retinopathy (DR) by measuring macular ganglion cell-inner plexiform layer (mGCIPL) thickness in patients with type 2 diabetes (T2DM).

Design: Retrospective cohort study.

Methods: T2DM patients with no DR or mild nonproliferative DR (NPDR) followed up for ≥4 years were included in this study. DR was graded according to retinal photography, and mean parafoveal mGCIPL thickness was measured using optical coherence tomography with at least a 6-month interval from baseline. Hazard ratios (HR) for predicting 2-step progression and development of proliferative DR (PDR) were calculated using Cox proportional hazard modeling using baseline clinical factors.

Results: Of 87 eyes of T2DM patients, 39 (44.8%) exhibited 2-step DR progression and 6 (6.9%) experienced progression to PDR. Patients with DR progression exhibited longer T2DM duration, thinner mGCIPL, greater mGCIPL thinning rate, severe cardiac autonomic neuropathy (CAN), lower peripheral nerve-conduction velocity, and higher glycated hemoglobin A1c level. Multivariate regression modeling revealed that baseline mGCIPL thickness (HR = 0.94), mGCIPL thinning rate (HR = 1.924), CAN score (HR = 1.248), and conduction velocity of peripheral nerves (HR = 0.894) were significant predictive factors for DR progression (area under the curve = 0.92).

Conclusion: Progressive loss of mGCIPL is an independent risk factor for progression in early-stage DR. Further assessment of autonomic and peripheral nerve functions can increase sensitivity in predicting aggravation of DR in patients with T2DM.

Citing Articles

Relationship of OCT-Based Diabetic Retinal Neurodegeneration to the Development and Progression of Diabetic Retinopathy: A Cohort Study.

Tang Z, Yang D, Nguyen T, Zhang S, Fang D, Chan V Invest Ophthalmol Vis Sci. 2025; 66(2):32.

PMID: 39932471 PMC: 11817850. DOI: 10.1167/iovs.66.2.32.


Comparisons of oscillatory potentials and 30 Hz flicker electroretinograms for discriminating eyes with diabetic retinopathy from normal eyes.

Gonmori M, Machida S, Inoue S, Ebihara S, Misu K Jpn J Ophthalmol. 2025; 69(1):49-58.

PMID: 39883242 DOI: 10.1007/s10384-024-01154-3.


Retinal Neurovascular Impairment in Full-Course Diabetic Retinopathy: The Guangdong Diabetic Retinopathy Multiple-Omics Study.

Lai C, Su T, Cao J, Li Q, Du Z, Wang Y Invest Ophthalmol Vis Sci. 2024; 65(14):20.

PMID: 39656471 PMC: 11636663. DOI: 10.1167/iovs.65.14.20.


Metabolomics combined with intestinal microbiota reveals the mechanism of compound Qilian tablets against diabetic retinopathy.

Jia J, Liu B, Wang X, Ji F, Wen F, Xu H Front Microbiol. 2024; 15:1453436.

PMID: 39220039 PMC: 11362098. DOI: 10.3389/fmicb.2024.1453436.


Cell and molecular targeted therapies for diabetic retinopathy.

Reddy S, Devi V, Seetharaman A, Shailaja S, Bhat K, Gangaraju R Front Endocrinol (Lausanne). 2024; 15:1416668.

PMID: 38948520 PMC: 11211264. DOI: 10.3389/fendo.2024.1416668.